HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplementary figure All Versions of this Article: 34/4/958    most recent 09031936.00165308v2 09031936.00165308v1 Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by De Luisi, A. Articles by Vacca, A. PubMed PubMed Citation Articles by De Luisi, A. Articles by Vacca, A.

Anti-angiogenic activity of carebastine: a plausible mechanism affecting airway remodelling

¹ Dept of Internal Medicine and Clinical Oncology, Unit of Allergology and Clinical Immunology, Bari, ⁴ Dept of Human Anatomy and Histology, University of Bari Medical School, Bari, ³ Almirall, Milan, Italy. ² Experimental Cardiovascular Medicine, Bristol Heart Institute, University of Bristol, Bristol, UK.

CORRESPONDENCE: A. Vacca, Dept of Internal Medicine and Clinical Oncology, Unit of Allergology and Clinical Immunology, Policlinico, Piazza Giulio Cesare, 11, I-70124 Bari, Italy. E-mail: a.vacca{at}dimo.uniba.it

Keywords: Allergic diseases, anti-angiogenesis, asthma, carebastine, ebastine, endothelial cells

Received: November 3, 2008
Accepted March 10, 2009

Ebastine is a well-known selective second-generation histamine H₁ receptor antagonist, which is used for seasonal and perennial allergic rhinitis and chronic urticaria. Angiogenesis plays a crucial role in the development of airway inflammation and remodelling in allergic rhinitis and asthmatic patients, in whom, indeed, the mucosa displays increased vascularity and overexpression of vascular endothelial growth factor (VEGF). The aim of the present study was to evaluate the anti-angiogenic properties of carebastine, the active metabolite of ebastine.

The effects of carebastine on human umbilical vein endothelial cell (EC) (HUVEC) and human pulmonary artery EC (HPAEC) proliferation, migration and capillary-like tube formation were investigated in vitro, and in the chick embryo chorioallantoic membrane (CAM) assay in vivo. Moreover, the effect of carebastine on phosphorylation of the cell VEGF receptor fetal liver kinase-1, or VEGF receptor 2 (VEGFR-2), and Akt kinase (Akt) was evaluated by Western blotting.

Carebastine inhibited VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner in vitro. Cell proliferation was inhibited by 42 and 64% in HUVECs and 62 and 75% in HPAECs upon exposure for 48 and 72 h, respectively, to 20 µM carebastine (p0.03), and even more with 30 µM carebastine. Cell migration was inhibited by 37 and 70% in HUVECs (p0.03) and 60 and 78% in HPAECs (p0.01) in the presence of 10 and 30 µM carebastine, respectively. Carebastine (20 µM) caused a significant reduction (70–86%; p<0.01) in topological parameters of the capillary network produced in vitro by both EC lines on a basement membrane extract. Carebastine (30 and 50 µM) inhibited the VEGF-induced angiogenesis in the CAM assay in vivo two- and three-fold, respectively (p<0.001). Finally, both EC lines, on exposure to 10 and 20 µM carebastine, showed a four- to six-fold reduction (p0.01) in both VEGF- and H₁ receptor-induced VEGFR-2 and Akt phosphorylation.

Overall, these data provide the first evidence regarding the anti-angiogenic activity of ebastine, and suggest its potential use as an anti-angiogenic molecule, besides its antihistaminic activity for the treatment of allergic diseases in which angiogenesis takes place.